A study of more than 205,000 patients with advanced cancer found that physician and practice factors influence clinical trial enrollment, highlighting opportunities to improve access and address participation disparities.
Feature|Articles|June 9, 2025
Fully Remote Telehealth Cancer Clinical Trial Aims to Expand Treatment Access Nationwide
Author(s)Tony Berberabe, MPH
Fact checked by: Sabrina Serani
A groundbreaking telehealth trial offers remote access to innovative pancreatic cancer treatment, enhancing patient participation and care coordination nationwide.
Advertisement
Advertisement
A fully remote phase 2 telehealth trial (NCT06906562)1 that delivers oral pancreatic treatment directly to patients’ homes while coordinating care with local oncologists was launched recently at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and the Richard J. Solove Research Institute (OSUCCC-James). The trial, which opened May 8, 2025, seeks to enroll patients with FGFR-mutated pancreatic cancer.
Related to this article
The perioperative regimen improved event-free and overall survival in the phase 3 VOLGA trial, offering a new option for patients with muscle-invasive bladder cancer who cannot receive or decline cisplatin.
Ravi Parikh, MD, MPP, discusses the future of oncology practice, including real-world data, patient engagement, emerging technologies, and policy priorities shaping cancer care.
Updated guidance recommends biennial prostate-specific antigen testing for average-risk men aged 50 to 69 years and annual screening beginning at age 45 for higher-risk men.
The NDA was completed for first-line zipalertinib plus platinum chemotherapy in EGFR exon 20 insertion NSCLC, based on phase 3 REZILIENT3 data showing improved PFS.
Telisotuzumab adizutecan showed promising survival in pretreated nonsquamous NSCLC, with the most benefit in EGFR wild-type tumors with high c-Met levels.
During a live event, Rushang Patel, MD, PhD, and participants discussed referral timing, bridging, and payer barriers that shape access to cellular therapy in early relapsed multiple myeloma.
The FDA granted RMAT and fast track designations to prizloncabtagene autoleucel , a CD20/CD19 bispecific CAR T-cell therapy, for relapsed/refractory large B-cell lymphoma.
Advertisement
Advertisement